Aruna Biomedical
Aruna Bio is dedicated to transforming the treatment of neurodegenerative and neurological diseases by developing innovative neural exosome platforms. With a focus on crossing the blood-brain barrier, their proprietary neural exosomes, such as AB126, demonstrate potential to reduce neuro-inflammation, promote neuroprotection, and stimulate neuro-regeneration. Their mission is to bring new hope to millions affected by these challenging conditions through scalable, dependable, and groundbreaking therapies.
Industries
Nr. of Employees
small (1-50)
Aruna Biomedical
Athens, Georgia, United States, North America
Products
Therapeutic neural exosome (lead program)
Allogeneic neural stem cell-derived extracellular vesicle intended as a CNS therapeutic and as a delivery vehicle for therapeutic cargos; demonstrated preclinical brain distribution, biological activity, and potential efficacy in stroke and other neurological disease models.
AB126
Allogenic neural exosomes derived from proprietary non-transformed neural stem cells, designed for CNS applications with the ability to cross the blood-brain barrier and concentrate in brain regions such as the cerebellum and basal ganglia. Used as a therapeutic agent or payload delivery system for siRNA, ASOs, and proteins like monoclonal antibodies.
AB126 therapeutic exosome
AB126 is a therapeutic exosome with CNS specificity, equipped with receptors and surface proteins that allow it to cross the blood-brain barrier and concentrate in the brain, including the cerebellum and basal ganglia.
Therapeutic neural exosome (lead program)
Allogeneic neural stem cell-derived extracellular vesicle intended as a CNS therapeutic and as a delivery vehicle for therapeutic cargos; demonstrated preclinical brain distribution, biological activity, and potential efficacy in stroke and other neurological disease models.
AB126
Allogenic neural exosomes derived from proprietary non-transformed neural stem cells, designed for CNS applications with the ability to cross the blood-brain barrier and concentrate in brain regions such as the cerebellum and basal ganglia. Used as a therapeutic agent or payload delivery system for siRNA, ASOs, and proteins like monoclonal antibodies.
AB126 therapeutic exosome
AB126 is a therapeutic exosome with CNS specificity, equipped with receptors and surface proteins that allow it to cross the blood-brain barrier and concentrate in the brain, including the cerebellum and basal ganglia.
Services
Development and optimization of loading therapeutic nucleic acids, proteins, and small molecules into neural-derived exosomes and evaluation of CNS delivery in preclinical models.
Manufacture of clinical-grade neural-derived exosome material with processes for isolation, purification, concentration, and batch reproducibility in a cGMP facility.
Development and optimization of loading therapeutic nucleic acids, proteins, and small molecules into neural-derived exosomes and evaluation of CNS delivery in preclinical models.
Manufacture of clinical-grade neural-derived exosome material with processes for isolation, purification, concentration, and batch reproducibility in a cGMP facility.
Expertise Areas
- CNS drug delivery
- Exosome therapeutics and extracellular vesicle engineering
- Neural stem cell-derived biologics
- Preclinical translational modeling (rodent and porcine stroke models)
Key Technologies
- Neural-derived extracellular vesicles (exosomes)
- Extracellular vesicle loading and formulation
- Imaging flow cytometry
- High-content imaging